Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping. Andrew Blauvelt, M.D. discussed new drugs in the pipeline during American Academy of Dermatology Annual Meeting in Washington, D.C. in March.
With a crowded indication that includes 14 systemic agents, is there really room for tyrosine kinase 2 (Tyk2) inhibitors to treat psoriasis? This physician thinks so.
While this new class of medications still has a role in treating psoriasis, this physician says the standard for both their efficacy and safety is very high because of the existing, already very effective systemic therapies available today.
In our first Irregular Borders column, Peter A. Lio, M.D., explores the evidence for leaky gut and its relevance in dermatology while highlighting parallels with impaired skin barrier function in conditions such as atopic dermatitis.
"Pretty much, I couldn’t go about my normal life," says Benjamin Sun about a life-altering eczema flare up at age 9, which left him out of school and bedridden for weeks. Until now, children like Sun didn’t have an effective, safe option for long-term disease control. Read how dupilumab changed his quality of life, and what it can do for your pediatric patients with uncontrolled moderate to severe atopic dermatitis.
